US Colorectal Cancer Screening Market Industry Trends and Forecast to 2034: Segmented by (Test, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$3.80 BnPlaceholder estimate
Estimate 2025$4.00 Bn46.6% of the global market
Projected 2034$6.43 Bn 60.5%Adds $2.42 Bn over 9 forecast years
CAGR 2025–20345.4%Faster than 39% of 180 Medical Devices markets here
76 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The US Colorectal Cancer Screening Market Analysis Executive Summary
Colorectal cancer screening finds bowel cancer and pre-cancer early, using stool tests, blood tests and colonoscopy.
Key segments of the colorectal Cancer Screening market include test (Stool DNA Tests, FIT Tests and Blood-Based Tests) and setting (At-Home, Clinics and Hospitals).
US Colorectal Cancer Screening market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
US Colorectal Cancer Screening Market Dynamics
Market Growth Drivers
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the colorectal Cancer Screening market. Faster approvals and new combinations are improving survival.
Opportunity
Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the colorectal Cancer Screening market.
Market Restraints
High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the colorectal Cancer Screening market, especially in low- and middle-income countries.
Competitive Landscape for Colorectal Cancer Screening Market in the US
The colorectal Cancer Screening market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Colorectal Cancer Screening Market in the US
Colorectal Cancer Screening in the US: rules, payment and research
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2] ClinicalTrials.gov lists 76 studies on Colorectal Cancer Screening that are recruiting, active or about to start in the US.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how colorectal Cancer Screening products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in the US.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Test
4.2 By Setting
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Exact Sciences
7.2 Guardant Health
7.3 Olympus Corporation
7.4 QuidelOrtho
7.5 Eiken Chemical
7.6 Fujifilm
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The colorectal Cancer Screening market can be segmented based on various criteria, including test, setting and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Colorectal Cancer Screening right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Colorectal Cancer Screening in context
The US compared
Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.
How big is the Colorectal Cancer Screening market in the US?
Placeholder estimate: about $4.00 Bn in 2025, rising to about $6.43 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Colorectal Cancer Screening market in the US growing?
Placeholder estimate: about 5.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Colorectal Cancer Screening market report cover?
The report splits the market by test (Stool DNA Tests, FIT Tests, Blood-Based Tests, Colonoscopy and more), setting (At-Home, Clinics, Hospitals) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Colorectal Cancer Screening market?
Key players include Exact Sciences Corporation, Guardant Health, Inc., Olympus Corporation, Quidel Corporation, Eiken Chemical and FUJIFILM Holdings Corporation.
What is driving the Colorectal Cancer Screening market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the colorectal Cancer Screening market. Faster approvals and new combinations are improving survival.
Who regulates Colorectal Cancer Screening in the US?
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA). Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Colorectal Cancer Screening are running in the US?
76 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
How much research is published on Colorectal Cancer Screening?
PubMed lists 3,251 papers on Colorectal Cancer Screening added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.